Since the pandemic began, the industry has overcome many obstacles while concentrating on rapidly deploying clinical trials, introducing new and repurposed treatments, and developing and rolling out new vaccines on groundbreaking technological platforms.

Today, more than 15 billion COVID-19 vaccines have been produced worldwide, facilitated by over 381 partnerships, voluntary licenses, and technology transfers.

Over 36 treatments have been approved for emergency use or standard of care including antivirals, anti-inflammatories, and monoclonal antibodies. Companies developing COVID-19 treatments entered into over 150 collaborations to expand manufacturing capacity.

IFPMA is a founding partner of the ACT-Accelerator and is fully committed to the goal of the WHO’s COVAX Pillar to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.

Almost 70% of the global population is now partially vaccinated. Despite this remarkable achievement, there’s still much to be done to achieve COVID-19 vaccine equity.  

Treatments are another important tool to fight COVID-19. Our industry has tested existing treatments and developed new ones, including antivirals, anti-inflammatories and monoclonal antibodies. It has prioritized equitable access by implementing multiple strategies, including over 150 voluntary licenses and tiered pricing.

Alongside its work in tackling COVID-19, the industry began reflecting on lessons learned that can inform how we create a healthier, safer, more equitable world. The innovative pharmaceutical industry proposes to turn these lessons into strategic insights that will guide future efforts to build effective pandemic preparedness and response.

This culminated in the groundbreaking Berlin Declaration in which industry proposes a framework to improve the real-time delivery of vaccines, treatments and diagnostics for priority populations in lower-income countries for future global pandemics